MCA
ELDN icon

McGuire Capital Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

McGuire Capital Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260 Hold
66
– – ﹤0.01% 853
2026
Q1 		$203 Buy
+66
New +$155 ﹤0.01% 829

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

McGuire Capital Advisors's ELDN Position: Q2 2026 in Review

McGuire Capital Advisors held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 66 shares worth $260. The position accounts for ﹤0.01% of the portfolio, ranked #853.

McGuire Capital Advisors first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • McGuire Capital Advisors held 66 shares of Eledon Pharmaceuticals worth $260 as of Q2 2026.
  • McGuire Capital Advisors left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #853 holding.
  • McGuire Capital Advisors first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.